259 related articles for article (PubMed ID: 19509135)
1. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
Blair BG; Larson CA; Safaei R; Howell SB
Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
[TBL] [Abstract][Full Text] [Related]
2. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
[TBL] [Abstract][Full Text] [Related]
3. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
Holzer AK; Manorek GH; Howell SB
Mol Pharmacol; 2006 Oct; 70(4):1390-4. PubMed ID: 16847145
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
5. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
Huang CP; Fofana M; Chan J; Chang CJ; Howell SB
Metallomics; 2014 Mar; 6(3):654-61. PubMed ID: 24522273
[TBL] [Abstract][Full Text] [Related]
6. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
Larson CA; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2009 Feb; 75(2):324-30. PubMed ID: 18996970
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
9. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
Bompiani KM; Tsai CY; Achatz FP; Liebig JK; Howell SB
Metallomics; 2016 Sep; 8(9):951-62. PubMed ID: 27157188
[TBL] [Abstract][Full Text] [Related]
10. Gene duplication and neo-functionalization in the evolutionary and functional divergence of the metazoan copper transporters Ctr1 and Ctr2.
Logeman BL; Wood LK; Lee J; Thiele DJ
J Biol Chem; 2017 Jul; 292(27):11531-11546. PubMed ID: 28507097
[TBL] [Abstract][Full Text] [Related]
11. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
Blair BG; Larson CA; Adams PL; Abada PB; Pesce CE; Safaei R; Howell SB
Mol Pharmacol; 2011 Jan; 79(1):157-66. PubMed ID: 20930109
[TBL] [Abstract][Full Text] [Related]
12. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.
Lin X; Okuda T; Holzer A; Howell SB
Mol Pharmacol; 2002 Nov; 62(5):1154-9. PubMed ID: 12391279
[TBL] [Abstract][Full Text] [Related]
13. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
14. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
Howell SB; Safaei R; Larson CA; Sailor MJ
Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
[TBL] [Abstract][Full Text] [Related]
15. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
Katano K; Safaei R; Samimi G; Holzer A; Rochdi M; Howell SB
Mol Pharmacol; 2003 Aug; 64(2):466-73. PubMed ID: 12869652
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
17. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
Safaei R; Maktabi MH; Blair BG; Larson CA; Howell SB
J Inorg Biochem; 2009 Mar; 103(3):333-41. PubMed ID: 19124158
[TBL] [Abstract][Full Text] [Related]
18. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Safaei R; Howell SB
Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
[TBL] [Abstract][Full Text] [Related]
19. Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain.
Öhrvik H; Nose Y; Wood LK; Kim BE; Gleber SC; Ralle M; Thiele DJ
Proc Natl Acad Sci U S A; 2013 Nov; 110(46):E4279-88. PubMed ID: 24167251
[TBL] [Abstract][Full Text] [Related]
20. The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).
Tsai CY; Liebig JK; Tsigelny IF; Howell SB
Metallomics; 2015 Nov; 7(11):1477-87. PubMed ID: 26205368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
